Advanced Oncotherapy raises £2m for proton therapy development

Proton therapy technology developer Advanced Oncotherapy announced an equity fundraise of £2m on Friday, to fund itself along its revised timetable for the development of the ‘LIGHT’ cancer therapy system.

  • Advanced Oncotherapy
  • 27 March 2024 17:20:27
Advanced Oncotherapy

Source: Sharecast

The AIM-traded firm said the fundraise was conducted through a direct subscription for eight million new shares at a price of 25p each.

It said the shares were subscribed for by Odey Asset Management, acting on behalf of its funds.

The issue price represented a premium of 6.38% to the closing middle-market price of the company’s shares on Thursday.

Under the subscription, warrants for eight million new shares would be issued on 1 April to the funds, with an exercise price of 25p each and exercisable up until 31 March 2026.

Advanced Oncotherpay also said that on Wednesday, it entered into a new short-term loan agreement of £1.5m with Nerano Pharma - a company owned and controlled by significant shareholder Seamus Mulligan - with an interest rate of 1.25% per month.

The loan would be repayable on 24 June.

As part of the agreement, the firm said it would issue 6,382,978 warrants to Nerano Pharma with an exercise price of 28.2p per share, exercisable until 24 March 2025.

“The funds raised from the subscription, as well as the funds available to the company pursuant to the loan, will be used for general corporate purposes as the company progresses along its revised target timescale of summer 2022 for having a fully-operational LIGHT system operating at 230 MeV,” the board said in its statement.

At 1252 GMT, shares in Advanced Oncotherapy were up 4.79% at 24.62p.

N/A

Isin: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

Whether you're looking for a Share Dealing Account or Share Dealing ISA, we've got an account to suit your needs.

Lloyds Bank is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

The Lloyds Bank Direct Investments Service is operated by Halifax Share Dealing Limited. Registered Office: Trinity Road, Halifax, West Yorkshire, HX1 2RG. Registered in England and Wales no. 3195646. Halifax Share Dealing Limited is authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under registration number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2024 Refinitiv, an LSEG business. All rights reserved.